Author: Ben Auch

Phase Genomics Launches ProxiMeta™ Starter and Elite Bundles to Expand Access to Genome-Resolved Metagenomics

Posted on June 18, 2025 by - Uncategorized

The new suite of products unlocks greater access to deep metagenomic research, accelerating discovery from complex microbial communities in human and environmental research applications.

 

SEATTLE – June 19, 2025 – Phase Genomics, Inc., a leader in genomic technology development, today announced the launch of its new ProxiMeta Starter and Elite Bundles, comprehensive product offerings that make genome- and mobilome-resolved metagenomics more accessible for researchers across microbiome, environmental and public health applications. Built on Phase Genomics’ award-winning Hi-C metagenomics platform, the streamlined, full-service solutions accelerate discovery from within complex microbial communities.

“We built the ProxiMeta bundles to meet researchers exactly where they are, whether just getting started or leading large-scale research projects. Research doesn’t look the same today as it did even last year. Labs are being asked to do more with fewer resources across the board, and we’re here to help,” said Ivan Liachko, PhD, CEO and co-founder of Phase Genomics. “The ProxiMeta bundles offer a flexible platform that evolves with a researcher’s career and their science.”

The two new bundles provide a scalable entry point for new users and a hands-off option for labs looking to outsource highly specialized technical workflows. The Starter and Elite bundles for Hi-C metagenomics combine robust sequencing, dynamic bioinformatics and personalized scientific support into ready-to-use formats, without the constraints of 16S-based techniques or culturing.

 

  • The ProxiMeta Starter Bundle is tailored for early-career researchers new to next-generation metagenomics, offering an affordable on-ramp to advanced microbial insights for up to two samples with guaranteed success on library prep. If the initial library preparation fails, Phase Genomics will re-prep the sample at no additional cost. Starter includes hands-on support from Phase Genomics scientists. Learn more here.
  • The ProxiMeta Elite Bundle offers a turnkey, remote extension of lab operations for experienced investigators with active funding and limited bench time. The bundle includes deep metagenomic shotgun sequencing and Hi-C assembly for up to eight samples, performed entirely in-house at Phase Genomics. Learn more here.

 

ProxiMeta Classic is still available as an à la carte option for researchers who prefer to customize their project scope or perform sequencing and analysis in-house. Classic delivers the same high-resolution capabilities with the flexibility of tailored support when needed.

 

The ProxiMeta platform has been heavily cited in leading peer-reviewed journals for its ability to generate high-quality genomes, resolve microbial population structure and link mobile genetic elements like plasmids and phages to their microbial hosts. The ProxiMeta Starter and Elite Bundles are available beginning today, June 19, 2025. For more information or to request a consultation, stop by booth 1109 at ASM 2025 or click here to learn more.

 

Follow Phase Genomics on X and LinkedIn for the latest information.

About Phase Genomics

Phase Genomics applies proprietary ultra-long-range genome sequencing technology to enable genome assembly, microbiome discovery, as well as analysis of genomic integrity and chromosomal aberrations. In addition to a comprehensive portfolio of laboratory and computational services and products, including reagent kits and genomic services, they also offer an industry-leading genome and metagenome assembly and analysis software. Based in Seattle, WA, the company was founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs. The company’s mission is to empower scientists with genomic tools that accelerate breakthrough discoveries.

Phase Genomics Presents Data on Genomic Proximity Mapping™ (GPM) for Next-Generation Cytogenetics at the AACR Annual Meeting 2025

Posted on April 25, 2025 by - Cytogenomics, Genomics, Hi-C, Science

Data show that GPM recapitulates or exceeds performance of standard-of-care diagnostics for cytogenetic analysis in the research setting

 

SEATTLE – April 25, 2025 –Phase Genomics, Inc., a leading innovator at the forefront of genomic technology development, today announced data from two studies in sarcoma and head and neck squamous cell carcinoma (HNSCC) demonstrating superior performance of AI-powered Genomic Proximity Mapping™ at the American Association of Cancer Research (AACR) Annual Meeting 2025.

     “Our data at AACR validate a GPM paradigm shift for cytogenetic analysis, extending  utility across all cancer types. We’re revealing structural variants and chromosome abnormalities that remain hidden to conventional methods, providing researchers with unprecedented genomic insights, even in challenging sample formats like FFPE,” said Ivan Liachko, PhD, co-founder and CEO of Phase Genomics. “The studies presented this year demonstrate how our AI-powered tech simplifies workflows while expanding our ability to detect clinically relevant genomic alterations. It’s a critical advancement toward more comprehensive cancer characterization and the potential to unlock new therapeutic paths for patients.”

     GPM is a genome-wide, DNA-based assay that overcomes the limitations of current cytogenetics approaches. Data presented at AACR showcase the utility of the CytoTerra® platform, powered by GPM, to extend previously unavailable cytogenetic analysis to solid tumor cancers in a single assay, without the need for labor- and time-intensive reflex testing in standard-of-care diagnostics. The platform is amenable to a wide variety of sample types, including formalin-fixed, paraffin-embedded (FFPE) tissues, making it ideally suited to extend and accelerate cytogenetic analysis for all cancer types and sample formats.

 

Presentation Details
Poster 6634 / 15: Enhanced detection of gene fusions in sarcoma FFPE tissue using Genomic Proximity Mapping

Data presented at AACR support Phase Genomics’ genome-wide approach to identify known and novel gene fusions and other classes of chromosome abnormalities in 12 sarcoma FFPE samples that previously failed common cytogenetic tests. Findings suggest that GPM may be used to enhance classification of sarcoma stored in FFPE blocks where other methods fail:

  • GPM was concordant with established findings or added additional pathognomonic findings
  • In samples that failed standard clinical assays, GPM was able to identify actionable variants
  • Identified novel structural variants across the genome that may be clinically relevant for subtyping
Poster 716 / 1: Discovery of biomarkers of brain metastasis using Genomic Proximity Mapping (GPM) on formalin-fixed paraffin-embedded head and neck squamous cell carcinomas

Analysis of GPM in two primary HNSCC tumors with brain metastasis and three non-metestatic HNSCC samples identified variants that allow inferences on tumor evolution. Notably, GPM identified alterations in known and targetable oncogenes in metastatic HNSCC samples, including:

  • Structural rearrangements involving the JAK1 and EGFR loci in both samples, as well as a potential NRG1::FAM110B fusion in one case of metastatic HNSCC
  • Structural alterations occurred outside the coding regions of the gene and would not be detected through standard panel sequencing
  • Data support GPM as a tool for novel biomarker discovery in solid tumors, including HNSCC

CytoTerra is available for research use only and is not for use as a clinical diagnostic.

Discover next-generation cytogenetics powered by GPM and connect with the Phase Genomics team. Follow Phase Genomics on LinkedIn, X and Bluesky for the latest company news and information.

 

About Phase Genomics

Phase Genomics applies proprietary ultra-long-range genome sequencing technology to enable genome assembly, microbiome discovery, as well as analysis of genomic integrity and chromosomal aberrations. In addition to a comprehensive portfolio of laboratory and computational services and products, including reagent kits and genomic services, they also offer an industry-leading genome and metagenome assembly and analysis software. Based in Seattle, WA, the company was founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs. The company’s mission is to empower scientists with genomic tools that accelerate breakthrough discoveries.